Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in Interest ReceivablesFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Marker Therapeutics (MRKR) Gains from Investment Securities (2016 - 2025)

Historic Gains from Investment Securities for Marker Therapeutics (MRKR) over the last 9 years, with Q3 2025 value amounting to $700461.0.

  • Marker Therapeutics' Gains from Investment Securities rose 1746.14% to $700461.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $700461.0, marking a year-over-year increase of 1746.14%. This contributed to the annual value of $587704.0 for FY2024, which is 2035.4% down from last year.
  • Marker Therapeutics' Gains from Investment Securities amounted to $700461.0 in Q3 2025, which was up 1746.14% from $709261.0 recorded in Q2 2025.
  • Over the past 5 years, Marker Therapeutics' Gains from Investment Securities peaked at $10.0 million during Q3 2022, and registered a low of $587704.0 during Q4 2024.
  • For the 5-year period, Marker Therapeutics' Gains from Investment Securities averaged around $2.9 million, with its median value being $768894.5 (2023).
  • Its Gains from Investment Securities has fluctuated over the past 5 years, first soared by 2535.26% in 2022, then tumbled by 9197.03% in 2023.
  • Quarter analysis of 5 years shows Marker Therapeutics' Gains from Investment Securities stood at $7.5 million in 2021, then crashed by 88.17% to $886173.0 in 2022, then fell by 16.73% to $737895.0 in 2023, then dropped by 20.35% to $587704.0 in 2024, then grew by 19.19% to $700461.0 in 2025.
  • Its last three reported values are $700461.0 in Q3 2025, $709261.0 for Q2 2025, and $727704.0 during Q1 2025.